Abstract
The emergence of drug resistant pathogens can reduce the efficacy of drugs commonly used to treat infectious diseases. Human immunodeficiency virus (HIV) is particularly sensitive to drug selection pressure, rapidly evolving into drug resistant variants on exposure to anti-HIV drugs. Over 200 mutations within the genetic material of HIV have been shown to be associated with drug resistance to date, and complex mutational patterns have been found in HIV isolates from infected patients exposed to multiple antiretroviral drugs. Genotyping is commonly used in clinical practice as a tool to identify drug resistance mutations in HIV from individual patients. This information is then used to help guide the choice of future therapy for patients whose drug regimen is failing because of the development of drug resistant HIV. Many sets of rules and algorithms are available to predict loss of susceptibility to individual antiretroviral drugs from genotypic data. Although this approach has been helpful, the interpretation of genotypic data remains challenging. We describe here the development and application of ANN models as alternative tools for the interpretation of HIV genotypic drug resistance data.
A large amount of clinical and virological data, from around 30,000 patients treated with antiretroviral drugs, has been collected by the HIV Resistance Response Database Initiative (RDI, www.hivrdi.org) in a centralized database. Treatment change episodes (TCEs) have been extracted from these data and used along with HIV drug resistance mutations as the basic input variables to train ANN models. We performed a series of analyses that have helped define the following: (1) the reliability of ANN predictions for HIV patients receiving routine clinical care; (2) the utility of ANN models to identify effective treatments for patients failing therapy; (3) strategies to increase the accuracy of ANN predictions; and (4) performance of ANN models in comparison to the rules-based methods currently in use.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ahmed FE (2005) Artificial neural networks for diagnosis and survival prediction in colon cancer. Mol Cancer 4:29–41.
Jerez JM, Franco L, Alba E, Llombart-Cussac A, Lluch A, Ribelles N, et al. (2005) Improvement of breast cancer relapse prediction in high risk intervals using artificial neural networks. Breast Cancer Res Treat 94:265–272.
Anagnostou T, Remzi M, Lykourinas M, Djavan B (2003) Artificial neural networks for decision-making in urologic oncology. Eur Urol 43:596–603.
Suzuki K, Li F, Sone S, Doi K (2005) Computer-aided diagnostic scheme for distinction between benign and malignant nodules in thoracic low-dose CT by use of massive training artificial neural network. IEEE Trans Med Imaging 24:1138–1150.
Baxt WG, Shofer FS, Sites FD, Hollander JE (2002) A neural computational aid to the diagnosis of acute myocardial infarction. Ann Emerg Med 39:366–373.
George J, Ahmed A, Patnaik M, Adler Y, Levy Y, Harats D, et al. (2000) The prediction of coronary atherosclerosis employing artificial neural networks. Clin Cardiol 23:453–456.
Zini G (2005) Artificial intelligence in hematology. Hematology 10:393–400.
Solomon I, Maharshak N, Chechik G, Leibovici L, Lubetsky A, Halkin H, et al. (2004) Applying an artificial neural network to warfarin maintenance dose prediction. Isr Med Assoc J 6:732–735.
Huang L, Yu P, Ju F, Cheng J (2003) Prediction of response to incision using the mutual information of electroencephalograms during anaesthesia. Med Eng Phys 25:321–327.
Fuller J J, Emmett M, Kessel JW, Price PD, Forsythe, J. H. (2005) A comparison of neural networks for computing predicted probability of survival for trauma victims. WV Med J 101:120–125.
Bent P, Tan HK, Bellomo R, Buckmaster J, Doolan L, Hart G, et al. (2001) Early and intensive continuous hemofiltration for severe renal failure after cardiac surgery. Ann Thorac Surg 71:832–837.
Papik K, Molnar B, Schaefer R, Dombovari Z, Tulassay Z, Feher J (1995) Application of neural networks in medicine: a review. Diagnostics and Medical Technology 1:538–546.
Zhu Y, Williams S, Zwiggelaar R (2006) Computer technology in detection and staging of prostate carcinoma: a review. Med Image Anal 10:178–199.
Lisboa PJ, Taktak AF (2006) The use of artificial neural networks in decision support in cancer: a systematic review. Neural Netw (Feb 13) (Epub in press).
Crawford ED (2003) Use of algorithms as determinants for individual patient decision making: national comprehensive cancer network versus artificial neural networks. Urology 62 (6) Suppl 1:13–19.
Koss LG, Sherman, ME, Cohen MB, Anes AR, Darragh TM, Lemos LB, et al. (1997) Significant reduction in the rate of false-negative cervical smears with neural network-based technology (PAPNET testing system). Hum Pathol 28:1196–1203.
Sherman ME, Schiffman MH, Mango LJ, Kelly D, Acosta D, Cason Z, et al. (1997) Evaluation of PAPNET testing as an ancillary tool to clarify the status of the “atypical” cervical smear. Mod Pathol10:564–571.
Babaian RJ, Fritsche H, Ayala A, Bhadkamkar V, Johnston DA, Naccarato W, et al. (2000) Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL. Urology 56:1000–1006.
Zlotta AR, Remzi M, Snow PB, Schulman CC, Marberger M, Djavan B (2003) An artificial neural network for prostate cancer staging when serum prostate specific antigen is 10 ng./ml or less. J Urol 169:1724–1728.
Egmont-Petersen M, de Ridder D, Handels H (2002) Image processing with neural networks-a review. Pattern Recognition 35:2279–2301.
Sordo M (2002) Introduction to neural networks in healthcare. Open Clinical. [online] www.openclinical.org/docs/int/neuralnetworks011.pdf.
Wang D, Larder B (2003) Enhanced prediction of lopinavir resistance from genotype by use of artificial neural networks. J Infect Dis 188:653–660.
The Panel on Clinical Practices for Treatment of HIV Infection Convened by the Department of Health and Social Services. (2006) Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents, October 6, 2005. [online] http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
Harrigan PR, Hogg RS, Dong WW, Yip B, Wynhoven B, Woodward J, et al. (2005) Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 191:339–347.
Wang D, De Gruttola V, Hammer S, Harrigan R, Larder B, Wegner S, et al., on Behalf of the HIV Resistance Response Database Initiative. (2002). A collaborative HIV resistance response database initiative: predicting virological response using neural network models. Antiviral Therapy 7:S96.
Wang D, Larder BA, Revell A, Harrigan R, Montaner J, on behalf of the HIV Resistance Response Database Initiative. (2003). A neural network model using clinical cohort data accurately predicts virological response and identifies regimens with increased probability of success in treatment failures. Antiviral Therapy 8:S112.
Larder BA, Wang D, Revell A, Lane C (2003) Neural network model identified potentially effective drug combinations for patients failing salvage therapy. 2nd IAS conference on HIV pathogenesis and treatment, Paris, July 13–16, poster LB39.
Larder BA, Wang D, Revell A, Harrigan R, Montaner J, Lane C (2004) Accuracy of neural network models in predicting HIV treatment response from genotype may depend on diversity as well as size of data sets. 11th conference on retroviruses and opportunistic infections, San Francisco, February 8–11, poster 697.
Revell A, Larder BA, Wang D, Wegner S, Harrigan R, Montaner J, Lane C (2005) Global neural network models are superior to single clinic models as general quantitative predictors of virologic treatment response. 3rd IAS conference on HIV pathogenesis and treatment. July 24–27, Rio de Janeiro, poster WePe12.6C04.
Wang D, Larder BA, Revell A, Harrigan R, Montaner J, Wegner S, Lane C (2005) Treatment history improves the accuracy of neural networks predicting virologic response to HIV therapy. BioSapiens-viRgil workshop on bioinformatics for viral infections, September 21–23, Caesar Bonn, Germany, poster 20.
Larder BA, Wang D, Revell A, Harrigan R, Montaner J,Wegner S, Lane C (2005) Treatment history but not previous genotype improves the accuracy of predicting virologic response to HIV therapy. 45th ICAAC, December 16–19. Washington, DC, poster H-1051.
Larder BA, Wang D, Revell A, Harrigan R, Montaner J, Wegner S, Lane C (2005). Treatment history and adherence information significantly improves prediction of virological response by neural networks. Antiviral Therapy 10:S57.
Larder BA, Revell A, Wang D, Harrigan R, Montaner J, Wegner S, Lane C (2005) Neural networks are more accurate predictors of virological response to HAART than rules-based genotype interpretation systems. 10th European AIDS conference/EACS, November 17–20, Dublin, poster PE3.4/13
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press, a part of Springer Science + Business Media, LLC
About this protocol
Cite this protocol
Larder, B., Wang, D., Revell, A. (2008). Application of Artificial Neural Networks for Decision Support in Medicine. In: Livingstone, D.J. (eds) Artificial Neural Networks. Methods in Molecular Biology™, vol 458. Humana Press. https://doi.org/10.1007/978-1-60327-101-1_7
Download citation
DOI: https://doi.org/10.1007/978-1-60327-101-1_7
Publisher Name: Humana Press
Print ISBN: 978-1-58829-718-1
Online ISBN: 978-1-60327-101-1
eBook Packages: Springer Protocols